INmune Bio is advancing two key programs: CORDStrom for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and XPro1595 for Alzheimer's Disease (AD). The CORDStrom program for RDEB has completed a randomized, placebo-controlled crossover Phase III trial (Mission EB) showing comprehensive organ system improvements, including itch and pain relief, skin quality, gastrointestinal symptoms, and overall wellbeing. CORDStrom is positioned as a first-in-class systemic therapy for RDEB, addressing multi-organ pathology, with an anticipated annual reimbursement of approximately $700,000 per patient and a potential total addressable market of over $1.4 billion. The XPro1595 program for Alzheimer's Disease presented positive Phase 2 MINDFuL trial data in an ADi (Alzheimer's Disease with Inflammation) enriched population, demonstrating clinically meaningful effects on cognitive composite (EMACC, d=0.27), cortical disarray (d=0.32), and neuropsychiatric symptoms (NPI Total Score, d=0.23). XPro1595 exhibited a differentiated safety profile in Phase 2, with no ARIA events despite a high-risk patient population and lower serious and severe adverse events compared to placebo. The company has completed an End-of-Phase 2 meeting with the FDA, aligning on an adaptive Phase 2b/3 trial design, endorsement of the ADi biomarker strategy, and CDR-SB as the sole Phase 3 primary endpoint.